Atinary and Takeda forge a strategic alliance to advance healthcare innovation

Atinary Technologies, a Vaud-based machine learning specialist, has joined forces with Takeda, Japan’s largest pharmaceutical entity, to spearhead innovation in healthcare.

Atinary Technologies, known for its revolutionary Self-Driving Labs (SDLabs) platform, is at the forefront of integrating machine learning (ML) into the R&D workflows of various industries, including pharmaceuticals. By adopting Atinary’s SDLabs technology, Takeda aims to refine its drug discovery and development processes, ensuring a more streamlined approach that could significantly shorten the time it takes to bring new therapies to market.

This strategic partnership is set to merge Atinary’s cutting-edge AI technology with Takeda’s extensive expertise in pharmaceutical research and development (R&D), promising to fast-track drug discovery and enhance the efficiency of the drug development process.

Takeda, with its rich history dating back to 2019 in Neuchâtel, post-acquisition of UK-based Shire, has been a pivotal player in global healthcare. The company’s investment in expanding its production capabilities and its dedication to innovation aligns with Atinary’s mission to expedite the discovery and development of breakthrough molecules and materials through its robust ML platform.

The strategic collaboration between Atinary and Takeda is a landmark initiative that combines Atinary’s prowess in AI, data science, robotics, and cloud computing with Takeda’s deep-rooted expertise in pharmaceutical R&D. Together, they aim to unlock new possibilities in drug discovery, making strides towards developing treatments that could significantly impact patients’ lives worldwide.